Aminophylline

Aminophylline is a competitive and non-selective phosphodiesterase (PDE) inhibitor. Aminophylline is a competitive adenosine receptor antagonist. Aminophylline has apulmonary vasodilator action as well as a bronchodilator action and has the potential for asthma research[1][2].

Product Specifications

CAS Number

[317-34-0]

UNSPSC

12352005

Hazard Statement

H301

Target

Adenosine Receptor; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Aminophylline.html

Purity

99.68

Solubility

DMSO : 14.29 mg/mL (ultrasonic) |H2O : 6.25 mg/mL (ultrasonic)

Smiles

O=C(N1C)N(C)C2=C(N=CN2)C1=O.O=C(N3C)N(C)C4=C(N=CN4)C3=O.NCCN

Molecular Formula

C16H24N10O4

Molecular Weight

420.43

Precautions

H301

References & Citations

[1]Daly JW, et al. Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63.|[2]Ming-Chih Yu, et al. Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia. ur J Pharmacol. 2010 Feb 10;627 (1-3) :269-75.|[3]E Tai, et al. Response of blood gas tensions to aminophylline and isoprenaline in patients with asthma. Thorax. 1967 Nov;22 (6) :543-9.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

3 Biotech. 2025 Apr;15 (4) :72.|Biol Proced Online. 2025 Jun 16;27 (1) :21.|Cell Chem Biol. 2025 Sep 18;32 (9) :1140-1149.e3.|Cell Rep Med. 2023 Jun 20;4 (6) :101061.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Eur J Drug Metab Pharmacokinet. 2022 Sep;47 (5) :639-652.|Exp Brain Res. 2024 Aug;242 (8) :1983-1998.|Int J Mol Sci. 2023 Jan 5;24 (2) :1019.|Int J Mol Sci. 2024 Mar 3;25 (5) :2947.|Int J Mol Sci. 2025 Nov 10;26 (22) :10883.|Pharmacol Res Perspect. 2020 Apr;8 (2) :e00575.|Research Square Preprint. 2020 Oct.